<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3730">
  <stage>Registered</stage>
  <submitdate>7/06/2012</submitdate>
  <approvaldate>7/06/2012</approvaldate>
  <nctid>NCT01616524</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3</studytitle>
    <scientifictitle>A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, With and Without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naïve Genotype 2 and 3 Chronic Hepatitis C Subjects</scientifictitle>
    <utrn />
    <trialacronym>PRINCIPAL</trialacronym>
    <secondaryid>2011-004885-14</secondaryid>
    <secondaryid>AI452-017</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C Virus (HCV)</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Pegylated interferon lambda (pegIFN?)
Other interventions - Pegylated interferon lambda (pegIFN?)
Other interventions - Pegylated interferon alfa-2a (pegIFNa-2a)
Treatment: drugs - Ribavirin
Treatment: drugs - Ribavirin
Treatment: drugs - Daclatasvir
Treatment: drugs - Placebo matching Daclatasvir

Experimental: Arm 1: pegIFN? + Ribavirin + Placebo matching Daclatasvir - 

Experimental: Arm 2: pegIFN? + Ribavirin + Daclatasvir - 

Experimental: Arm 3: pegIFNa-2a + Ribavirin + Placebo matching Daclatasvir - 


Other interventions: Pegylated interferon lambda (pegIFN?)
Syringe, Subcutaneous, 180 µg, Once weekly, 24 weeks

Other interventions: Pegylated interferon lambda (pegIFN?)
Syringe, Subcutaneous, 180 µg, Once weekly, 12 weeks

Other interventions: Pegylated interferon alfa-2a (pegIFNa-2a)
Syringe, Subcutaneous, 180 µg, Once weekly, 24 weeks

Treatment: drugs: Ribavirin
Tablets, Oral, 400 mg, Twice daily, 24 weeks

Treatment: drugs: Ribavirin
Tablets, Oral, 400 mg, Twice daily, 12 weeks

Treatment: drugs: Daclatasvir
Tablets, Oral, 60 mg, Once daily, 12 weeks

Treatment: drugs: Placebo matching Daclatasvir
Tablets, Oral, 0 mg, Once daily, 12 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of subjects who achieve Sustained Virologic Response at post-treatment follow-up week 12 (SVR12)</outcome>
      <timepoint>Post-treatment follow-up week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with Rapid virologic response (RVR) [undetectable Hepatitis C virus (HCV) Ribonucleic acid (RNA)]</outcome>
      <timepoint>On-treatment Week 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with treatment emergent cytopenic abnormalities (anemia as defined by Hb &lt; 10 g/dL, neutropenia as defined by ANC &lt; 750 mm3 or thrombocytopenia as defined by platelets &lt; 50,000 mm3) - Hb = Hemoglobin ANC = Absolute neutrophil count</outcome>
      <timepoint>Up to week 12 or week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with on-treatment interferon-associated flu-like symptoms (as defined by pyrexia or chills or pain)</outcome>
      <timepoint>Up to week 12 or week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with on-treatment musculoskeletal symptoms (as defined by arthralgia or myalgia or back pain)</outcome>
      <timepoint>Up to week 12 or week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with Sustained Virologic Response at post-treatment follow-up week 24 (SVR24) by treatment group</outcome>
      <timepoint>Post-treatment week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with on-treatment Serious adverse events (SAEs)</outcome>
      <timepoint>Up to week 12 or week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with dose reductions</outcome>
      <timepoint>Up to week 12 or week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects who discontinue due to Adverse events (AEs)</outcome>
      <timepoint>Up to week 12 or week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with SVR12 in subjects with genotype-3 (GT-3) chronic HCV infection</outcome>
      <timepoint>Post-treatment follow-up week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with on-treatment constitutional symptoms (fatigue or asthenia)</outcome>
      <timepoint>Up to week 12 or week 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        

          -  Chronic hepatitis C, Genotype 2 or 3

          -  Naïve to prior anti-HCV therapy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Infected with HCV other than Genotype 2 or 3

          -  Positive Hepatitis B surface antigen (HBsAg), or Human immunodeficiency virus-1
             (HIV-1)/HIV-2 antibody at screening

          -  Evidence of liver disease other than HCV

          -  Active substance abuse

          -  Evidence of decompensated cirrhosis</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>880</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Local Institution - Camperdown</hospital>
    <hospital>Local Institution - Concord</hospital>
    <hospital>Local Institution - Darlinghurst</hospital>
    <hospital>Local Institution - Randwick</hospital>
    <hospital>Local Institution - Westmead Nsw</hospital>
    <hospital>Local Institution - Brisbane</hospital>
    <hospital>Local Institution - Greenslopes</hospital>
    <hospital>Local Institution - Herston</hospital>
    <hospital>Local Institution - Adelaide</hospital>
    <hospital>Local Institution - Clayton Vic</hospital>
    <hospital>Local Institution - Fitzroy</hospital>
    <hospital>Local Institution - Melbourne</hospital>
    <hospital>Local Institution - Parville</hospital>
    <hospital>Local Institution - Fremantle</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2139 - Concord</postcode>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>2145 - Westmead Nsw</postcode>
    <postcode>4102 - Brisbane</postcode>
    <postcode>4120 - Greenslopes</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3168 - Clayton Vic</postcode>
    <postcode>3065 VIC - Fitzroy</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>3050 - Parville</postcode>
    <postcode>6160 - Fremantle</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Santa Fe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Cordoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Metropolitana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Hus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clichy Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Creteil Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier Cedex 5</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice Cedex 3</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaloniki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Tai Po</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Firenze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Napoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Novara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukuoka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hiroshima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hokkaido</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hyogo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ibaraki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kagawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kagoshima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kanagawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Okayama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Saitama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Wakayama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Miyazaki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Saga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Busan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeongsangnam-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Incheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Distrito Federal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Guadalajara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Leiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Chelyabinsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Irkutsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Krasnoyarsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Samara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Smolensk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Tainan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Yunlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Humberside</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottinghamshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>West Midlands</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine if 24 weeks of treatment with Pegylated Interferon
      Lambda plus Ribavirin and 12 weeks of treatment with Pegylated Interferon Lambda plus
      Ribavirin and Daclatasvir will be safe and effective for treatment of hepatitis C compared to
      24 weeks of treatment with Pegylated Interferon Alfa-2a plus Ribavirin</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01616524</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>